Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer, Starboard Value
Former Pfizer executives not involved in Starboard's campaign against drugmaker
CFO Frank D'Amelio said in a statement that they will not be involved with activist investor Starboard Value, which wants the U.S. drug giant to make changes to turn its performance around. "We are fully supportive of Pfizer Chairman and CEO Albert Bourla,
Former Pfizer CEO, finance chief step back from Starboard's activist campaign
Two former Pfizer executives who were previously linked to activist investor Starboard Value's campaign at the struggling drugmaker said they would step back from the push late Wednesday evening. Former CEO Ian Read and ex-CFO Frank D'Amelio voiced their full support for current CEO Albert Bourla and the management team.
Pfizer’s Former CEO Won’t Be Involved in Starboard Value Effort
Former Pfizer Inc. executives Ian Read and Frank D’Amelio have decided “not to be involved” in Starboard Value’s activist campaign against the drug company, according to statement released on their behalf late Wednesday.
Business Wire
2h
Pfizer Declares Fourth-Quarter 2024 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend on the ...
16h
What's Happening With Pfizer Stock?
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
1d
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...
1d
on MSN
Pfizer CEO’s Job Is at Risk. A Shot of Discipline Could Help.
As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.
bovnews
10h
The PFE Conundrum: Why Pfizer Inc’s Stock Is Making Headlines Again
On Tuesday, Pfizer Inc (PFE) stock saw a decline, ending the day at $29.18 which represents a decrease of $-0.02 or -0.07% from the prior close of $29.2. The stock opened at $29.21 and touched a low ...
1d
on MSN
Analysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
FierceBiotech
1d
'Ongoing challenges' force Pfizer to scrap oral RSV med from ReViral buyout
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
FiercePharma
1d
Pfizer, bracing for Hurricane Milton, pledges aid to emergency services and health support
Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Stocks
Covid-19
Starboard
RSV
Frank D'Amelio
Feedback